Compare AVTX & LOKV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTX | LOKV |
|---|---|---|
| Founded | 2011 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 294.7M |
| IPO Year | 2015 | 2025 |
| Metric | AVTX | LOKV |
|---|---|---|
| Price | $19.09 | $10.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 298.2K | 146.0K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $192,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.39 | $9.80 |
| 52 Week High | $20.72 | $11.67 |
| Indicator | AVTX | LOKV |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | N/A |
| Support Level | $17.18 | N/A |
| Resistance Level | $20.20 | N/A |
| Average True Range (ATR) | 1.72 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 69.94 | 0.00 |
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Live Oak Acquisition Corp V is a blank check company.